SCHEMBL17028346

SCHEMBL17028346

O=c1cc2c3ccccc3c3cc(=O)c4cccc1c4n23

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.42
▸ MAPT P10636 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ POLB P06746 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ LMNA P02545 1/20 0.39
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ PTPN1 P18031 1/20 0.36
▸ MAPK1 P28482 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ GPR3 P46089 1/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ ALKBH5 Q6P6C2 1/20 0.34
▸ FTO Q9C0B1 1/20 0.34
▸ ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17033180 0.91 ALDH1A1 (0.36) ALDH1A1MAPTHPGDKDM4EPOLB
SCHEMBL18387404 0.88 ALDH1A1 (0.34) ALDH1A1MAPTHPGDKDM4EPOLB
SCHEMBL17033332 0.86 ALDH1A1 (0.33) ALDH1A1MAPTHPGDKDM4EPOLB
SCHEMBL17028314 0.84 CYP1A2 (0.38) ALDH1A1MAPTHPGDKDM4EPOLB
SCHEMBL17033347 0.84 KDM4E (0.41) ALDH1A1MAPTHPGDKDM4EPOLB
SCHEMBL17033341 0.84 AHR (0.39) ALDH1A1MAPTHPGDKDM4EMEN1
SCHEMBL17028360 0.80 PGR (0.40) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL17028356 0.80 KIF11 (0.41) ALDH1A1MAPTHPGDKDM4EHTT
SCHEMBL17028363 0.80 TNKS (0.40) ALDH1A1MAPTHPGDKDM4EPOLB
SCHEMBL17033208 0.80 PGR (0.40) ALDH1A1MAPTHPGDKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170018717-A1 NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-01-19 — — US disclosed
US-20170018717-A1 NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-01-19 — — US disclosed
EP-3110817-A1 NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS BASF SE (DE) 2017-01-04 — — EP disclosed
WO-2015125125-A1 NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS BASF SE (DE) 2015-08-27 — — WO disclosed
WO-2015125125-A1 NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS BASF SE (DE) 2015-08-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170018717-A1 NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS CHRM2, RPS4Y1, CHRM4 ALDH1A1 3820/4885MAPT 4448/4885HPGD 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback